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Letter to the Editors-in-Chief
Heparin-induced thrombocytopenia and sepsis☆
Dear Sir,
We have read with great interest the paper “Anti-PF4/heparin an-
tibodies are increased in hospitalized patients with bacterial sepsis” by
Maharaj and co-workers [1] and we found it very important with a view
to clinical management of patients with heparin-induced thrombocy-
topenia.
The authors investigated the prevalence of anti-PF4/heparin anti-
bodies in patients hospitalized for sepsis. They confirmed that patients
hospitalized with sepsis have higher anti-PF4/heparin antibody levels.
The groups of patients having sepsis with bacteremia, and sepsis
without bacteremia, had significantly higher OD than the control group
without sepsis (p < 0.05). There was no significant difference between
Gram negative and Gram positive bacteremia and antibody levels.
With reference to the finding reported in the paper, we would like to
make the following contribution to the discussion. We retrospectively
analyzed data from 600 post-cardiac surgery patients in order to eval-
uate the incremental value of performing 4Ts Test and EuroSCORE test
for prediction of heparin-induced thrombocytopenia. [2]. Anti-PF4/
heparin antibodies were tested in all patients using a commercial im-
munoassay (Asserachrom H PF4 ELISA kits) [3–6]. Of the 600 patients
investigated, 131 (21.8%) were found to have anti-PF4/heparin anti-
bodies. The 4Ts score identified patients with the highest probability of
developing anti-PF4/heparin antibodies. In addition these patients had
the highest number of thrombotic events compared with patients with a
low probability 4Ts score [2].
Among the several parameters analyzed, bacteremia was similar in
patients with anti-PF4/heparin antibodies compared to patients
without antibodies (p=n.s.) and was not associated with an increased
risk of MACE (p=n.s.). In our sample no patients developed sepsis
and/or fungemia despite the high risk of infections of patients after
cardiac surgery.
The hypothesis that bacterial infection has a role to play in pre-
immunization leading to anti-PF4/heparin antibody generation is very
interesting [1]. A previous study found that antibodies magnify im-
mune responses induced in peripheral blood mononuclear cells by PF4
alone or in complex with heparin suggesting a link between in-
flammation and immune response in patients with HIT [7].
We agree with Maharaj S that it would be interesting to investigate
further in a larger study if there is an increased prevalence of anti-PF4/
heparin antibodies in patients hospitalized with bacterial but not fungal
sepsis.
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